DOCEBO
Leading AI-powered learning platform, Docebo Inc. (“Docebo”) (Nasdaq:DCBO; TSX:DCBO ), announced today the launch of a multi-product learning technology suite.
Previously, Docebo has focused on solving the problem of how organizations deliver training with its flagship learning management system (LMS). With the launch of Docebo Learning Suite, Docebo will go beyond content delivery and address challenges across the entire learning lifecycle, from content creation and management to measuring learning impact and key business drivers.
The launch of Docebo Learning Suite coincides with the launch of Docebo Shape, a content creation product built on AI. Developed internally, Docebo Shape enables businesses to bring more internal experts into their elearning content strategy by leveraging AI to create engaging learning content in minutes.
Including Docebo Shape, the core products that come together to transform the company’s offering into a cohesive learning suite include:
- Docebo Learn LMS, a top-rated Learning Management System that has been used by more than 2,000 customers;
- Docebo Shape, a content creation product that uses AI to create elearning content in minutes;
- Docebo Content, a library of thousands of off-the-shelf, mobile-ready learning courses, and;
- Docebo Learning Impact, a data-driven tool that allows users to measure the effectiveness of their learning programs on their people and improve ROI.
“Our vision is to build a learning suite for the future that addresses every enterprise learning requirement so our customers have a one-stop shop for all their learning needs,” said Docebo’s Chief Executive Officer, Claudio Erba. “Today’s announcement is the result of both a previous acquisition and internal R&D, and it’s a testament to the innovation that exists in Docebo’s DNA.”
To learn more about Docebo’s Enterprise Learning Suite, visit www.docebo.com .
About Docebo
Docebo is redefining the way enterprises leverage technology to create content, deliver training, and understand the business impact of their learning experiences. With Docebo's multi-product learning suite, enterprises around the world are equipped to tackle any learning challenge and create a true learning culture within their organization.
Forward-Looking Information
This press release may contain “forward-looking information” and “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities laws, including, without limitation, statements regarding: Company's business; future business strategy; the launch of new products and features; the learning management industry; our growth rates and growth strategies; addressable markets for our solutions; the achievement of advances in and expansion of our platform; expectations regarding our revenue and the revenue generation potential of our platform and other products; our business plans and strategies; and our competitive position in our industry.
This forward-looking information is based on our opinions, estimates and assumptions that, while considered by the Company to be appropriate and reasonable as of the date of this press release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including, without limitation: risks related to the COVID-19 pandemic and its impact on Docebo, economic conditions, and global markets; and other unforeseen events, developments, or factors causing any of the aforesaid expectations, assumptions, and other factors ultimately being inaccurate or irrelevant, and those factors discussed in greater detail under the “Risk Factors” section of our Annual Information Form for the year ended December 31, 2020, available under our profile on SEDAR at www.sedar.com , and should be considered carefully by prospective investors.
If any of these risks or uncertainties materialize, or if the opinions, estimates or assumptions underlying the forward-looking information prove incorrect, actual results or future events might vary materially from those anticipated in the forward-looking information. Although we have attempted to identify important risk factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other risk factors not presently known to us or that we presently believe are not material that could also cause actual results or future events to differ materially from those expressed in such forward-looking information. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. No forward-looking statement is a guarantee of future results. Accordingly, you should not place undue reliance on forward-looking information, which speaks only as of the date made. The forward-looking information contained in this press release represents our expectations as of the date specified herein, and are subject to change after such date. However, we disclaim any intention or obligation or undertaking to update or revise any forward-looking information whether as a result of new information, future events or otherwise, except as required under applicable securities laws.
All of the forward-looking information contained in this press release is expressly qualified by the foregoing cautionary statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210330005315/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
1NCE Continues Growth and Expands Its Software, AI and Services Offering7.1.2026 14:15:00 CET | Press release
In 2025 1NCE added another 10 million endpoints to its foundational IoT platform; now manages 40+ million intelligent products for 30,000 customers in 17 industries. Introduces new software, 1NCE Insights, the AI + IoT fusion of intelligence from its network that gives analytics and benchmark data on how customers can better setup, manage and optimize their device estates. 1NCE, a company offering a plug-and-play platform for creating and managing the world’s best IoT products, reports another strong growth year, adding another 10 million endpoints. The company now manages 40+ million intelligent products for 30,000+ customers across 17 industries. 1NCE’s software and connectivity platform has become a new industry standard, delivering hassle-free IoT in 170+ countries and regions. The company has a unique vantage point in the IoT ecosystem, with four billion data records per day collected through 250+ streams on the world’s largest IoT network in the cloud. The company launched a new
Prudentia Sciences Announces Series A Led by McKesson Ventures, Accelerating Due Diligence for Life Sciences Dealmaking7.1.2026 14:00:00 CET | Press release
Prudentia Sciences, a pioneer in AI-native due diligence for life sciences dealmaking, today announced that it has secured $20 million in Series A financing. The round was led by McKesson Ventures with participation from SignalFire. Existing investors include Iaso Ventures, Virtue and GV. This brings the company’s total funding to $27 million, following a $7 million seed round in 2024. Prudentia Sciences provides an AI-native platform that enables pharma companies, biotechs, and financial institutions to evaluate breakthrough medicines with unprecedented speed and rigor. By synthesizing complex clinical signals into actionable insights, Prudentia accelerates deal throughput and provides strategic leverage for acquisition, licensing, or investment decisions made by business development, investment, and diligence teams. The company’s human-in-the-loop approach orchestrates seamless collaboration between buyers, sellers, and intermediaries. This ensures a secure, compliant infrastructure
Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD7.1.2026 12:30:00 CET | Press release
FDA Accepts Investigational New Drug (IND) Application for COMP360 for the treatment of post-traumatic stress disorder (PTSD), enabling initiation of late-stage trialCompass continues to advance commercial preparations to be launch-ready by the end of the year for COMP360 for treatment-resistant depression (TRD)Management will host webinar with KOL and industry leaders to discuss PTSD clinical trial and commercial preparations for TRD from 10:00-11:30 am ET on January 7th Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company’s clinical trial plans for PTSD, as well as commercial preparations f
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 11:07:00 CET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 10:00:00 CET | Press release
CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
